We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 14, 2020

Preliminary Safety and Efficacy of DLYE5953A in Patients With Refractory Solid Tumors

Clinical Cancer Research


Additional Info

Clinical Cancer Research
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients With Refractory Solid Tumors
Clin. Cancer Res 2020 Jul 21;[EPub Ahead of Print], SM Tolaney, KT Do, JP Eder, PM LoRusso, CD Weekes, S Chandarlaplaty, CW Chang, SC Chen, D Nazzal, E Schuth, F Brunstein, M Carrasco-Triguero, W Darbonne, JM Giltnane, WM Flanagan, SR Commerford, A Ungewickell, GI Shapiro, S Modi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading